Auxilium Pharmaceuticals (NASDAQ: AUXL) shares were down a bit today on news that it is looking to merge -- in a $354 million, all-stock deal -- with Canada-based QLT (NVLN). Auxilium, which is well known for its testosterone treatments (like Testim) and erectile dysfunction drugs like Stendra, seems like a somewhat strange fit for QLT, which has a small pipeline focused on a pair of eye conditions.
So, why does Auxilium want QLT?
In the video below, health care analysts Michael Douglass and David Williamson answer.
